Innoviva, Inc. (NASDAQ: INVA) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
Innoviva, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $18.36, Innoviva, Inc. trades at 7.2x trailing earnings, 3.0x sales and 1.2x book value, with an EV/EBITDA of 1.7. Over the last twelve months it generated about $442M of revenue and $181M of net income. It runs a gross margin of 73.9%, an operating margin of 38.5% and a net margin of 43.8%. It shows return on equity of 15.8%, return on invested capital of 9.9% and a free cash flow yield of 13.9%. On the balance sheet: a debt-to-equity ratio of 0.24 and a current ratio of 15.44. Over the past 52 weeks the share price ranged from $18.30 to $25.15, with a beta of 0.33.
Innoviva, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 6 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Innoviva, Inc. (INVA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 17.1% / 30% · (Cash+Inv) / Mkt Cap (36m) 73.6% / 30% · Interest income / Revenue 5.01% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 17.1% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 38.9% / 33% · Receivables / Mkt Cap (36m) 6.73% / 49% · Interest income / Revenue 5.01% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 17.1% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 38.9% / 33.33% · Receivables / Mkt Cap (24m) 6.73% / 33.33% · Interest income / Revenue 5.01% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 16.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 34.7% / 33.33% · Receivables / Avg Assets (4Q) 5.07% / 33.33% · Interest income / Revenue 5.01% / 5% | Fail |
| FTSE | Debt / Total Assets 16.8% / 33.33% · (Cash+ST Inv) / Total Assets 38.4% / 33.33% · (Cash+Recv) / Total Assets 45.0% / 33.33% · Interest income / Revenue 5.01% / 5% | Fail |
No. As of September 2026, Innoviva, Inc. (INVA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Innoviva, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 5.01% of each dividend: Innoviva, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.